Media turns to APC in the post-compounded-GLP-1 world

Over the last few weeks, with the FDA declaring the end of the GLP-1 shortages, APC’s reporter hotline has been ringing off the hook* as news outlets pivot to writing about how this is going to affect patients. Here's just a sampling:

• “Zepbound copycats remain online despite FDA ban” from CNBC
• “Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get” from Newsday
• “Sale of Ozempic Knockoffs Is Supposed to End Soon. Telehealth Companies Aren’t Happy” from the Wall Street Journal
• “Will weight loss drugs remain affordable? Fort Worth compounding pharmacies concerned over FDA decision” from Fort Worth Report

* Kids, ask your parents